

APPLICANT:

Spertini  
U.S.S.N. 09/506,978

#### REMARKS

The instant amendment amends claims 28-30 of the instant application to more accurately reflect the nature of the invention. Applicant has also amended the specification to add a sequence identifier to the cysteine spacing motif recited on page 29, in the second full paragraph after Table 1 in the specification as filed. Additionally, Applicant submits a Sequence Listing for the nucleotide sequences disclosed in the specification in compliance with the requirements for patent applications containing nucleotide sequences and/or amino acid sequence disclosures. 37 C.F.R. §§ 1.821-1.825. Finally, Applicant has added new claims 36-46. Support for these claims is found in the specification as filed.

No new matter has been added by this amendment.

*Version with Markings to Show Changes Made****In the Specification:***

On page 29, the second full paragraph after Table 1:

-- EMBL and SWISS PROT data base searches for protein sequence homology and computer assisted protein analysis were done applying the Wisconsin Package Version 9.1 software (Genetics Computer Group, Madison, WI, USA). Database searches revealed that Api m 6 contained an epidermal growth factor-like domain signature which is shared by many otherwise unrelated proteins. Davis, *New Biol.* 2:410-419 (1990). No obvious homology to known proteins was found even when a profile search with the particular cysteine spacing motif "CX8CX3CX3CX8CX3CX3C" (SEQ ID NO:5), [( )where X is any amino acid()], was performed. --.

***In the Claims:***

1-27 *Withdrawn.*

28. (Amended) A method of modulating an immune response, said method comprising administering [the polypeptide of claim 1] a substantially pure polypeptide comprising an amino acid sequence at least 70% identical to the amino acid sequence of SEQ ID NO:1 to a subject in need thereof in an amount sufficient to inhibit an immune reaction by the subject against said polypeptide.

29. (Amended) The method of claim [25] 28, further comprising administering a second bee venom polypeptide to said subject.

30. (Amended) The method of claim 29, wherein the second bee venom polypeptide is selected from the group consisting of phospholipase A<sub>2</sub>, hyaluronidase, allergen C, mellitin, adolapin, minimine, acid phosphatase, protease inhibitor, and acid phosphatase, and glycosylated IgE-binding proteins, or analogs or derivatives thereof.

31-35. *Withdrawn.*

New claims 36- 46 were added.


APPLICANT:

Spertini  
U.S.S.N. 09/506,978

### CONCLUSION

On the basis of the foregoing amendments, Applicants respectfully submit that the pending claims are in condition for allowance. If there are any questions regarding these amendments and remarks, the Examiner is encouraged to contact either of the undersigned at the telephone number provided below.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529

Christina V. Karnakis, Reg. No. 45,899

Attorneys for Applicant

MINTZ, LEVIN et al.

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000

Fax: (617) 542-2241

Dated: June 5, 2001

TRA 1525032v1